Olema Oncology Issues Statement Regarding Falsified Information Circulating on Social Media

Rhea-AI Summary

Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) has issued a warning about falsified information circulating on social media regarding its planned poster presentation for the Phase 1 dose-escalation of OP-1250, part of an ongoing Phase 1/2 clinical trial at the San Antonio Breast Cancer Symposium. Olema clarifies that the unauthorized poster image was not released by the company. OP-1250 is being developed as a treatment for women with recurrent, locally advanced or metastatic ER-positive breast cancer.

Positive

• Olema's OP-1250 is advancing through a Phase 1/2 clinical trial, demonstrating ongoing commitment to women's cancer therapies.

Negative

• Falsified information regarding clinical presentations may undermine investor confidence and create confusion in the market.

SAN FRANCISCO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, has been alerted to falsified information circulating on social media relating to the company’s planned poster presentation for the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250 at the San Antonio Breast Cancer Symposium (SABCS). The falsified poster image was not released or authorized by the company.

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.

FAQ

What is the latest update from Olema Pharmaceuticals regarding OP-1250?

Olema Pharmaceuticals has warned about falsified social media information related to OP-1250's poster presentation at the San Antonio Breast Cancer Symposium.

What clinical trials is Olema currently conducting for OP-1250?

Olema is conducting a Phase 1/2 clinical trial for OP-1250 in patients with recurrent, locally advanced or metastatic ER-positive breast cancer.

How does the recent social media misinformation affect Olema (OLMA)?

The misinformation about Olema's clinical presentations could negatively impact investor confidence and market perception.